|
WO2020198054A1
|
|
Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia
|
|
WO2020056381A1
|
|
PROGRAMMABLE RNA-TEMPLATED SEQUENCING BY LIGATION (rSBL)
|
|
WO2020055768A1
|
|
Methods for treating pancreatitis
|
|
WO2020018893A1
|
|
(pyridinylmethyl)butanediamine derivatives that chelate copper
|
|
US2020376006A1
|
|
Method and compositions for forming a copper-containing complex and uses thereof
|
|
EP3624581A1
|
|
Compositions and methods for generating weak alleles in plants
|
|
MX2019013754A
|
|
Mutations in mads-box genes and uses thereof.
|
|
US2019343863A1
|
|
Modulation of lnc05 expression
|
|
WO2018089948A1
|
|
System and method for light sheet microscope and clearing for tracing
|
|
US2019241901A1
|
|
Control of meiotic crossover in maize
|
|
CA3020699A1
|
|
Florigen pathway toolkit
|
|
WO2017176829A1
|
|
Multiplexed analysis of neuron projections by sequencing
|
|
WO2017106283A1
|
|
Compositions and methods for treatment of liver diseases
|
|
CA3005246A1
|
|
Compositions and methods for treatment of central nervous system diseases
|
|
WO2017106370A1
|
|
Compositions and methods for treatment of eye diseases
|
|
KR20180093977A
|
|
Autosomal dominant mental retardation 5 and antisense oligomers for the treatment of Dravet syndrome
|
|
EP3390666A1
|
|
Compositions and methods for treatment of kidney diseases
|
|
CA3005131A1
|
|
Antisense oligomers for treatment of tuberous sclerosis complex
|
|
WO2017106364A2
|
|
Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
|
|
CA3005245A1
|
|
Antisense oligomers for treatment of alagille syndrome
|
